Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1/2
- “The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.”In the company’s words, NCT02584244 on ClinicalTrials.gov
Other drugs for Colorectal Cancer
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up1
- Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 10 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT02584244
- 10 NovCompletion date moved: 2026-12 to 2027-02 · ClinicalTrials.gov NCT02584244
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Feb 2027 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | |
| Phase 2Terminated | 30 Nov 2023 | Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients | |
| Phase 1/2Completed | Sep 2017 | Feasibility Study of Intraoperative Imaging in Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026